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Cherubism is a familial disorder of the jaws, 
which was first identified by Jones in 1933.1 The 
term “cherubism” has arisen from the char-
acteristic cherubic appearance of the patients. 
Cherubism is an autosomal dominant disease, and 
mutation of the exon 9 of the SH3BP2 gene has 
been identified in cherubism patients. Although 
penetrance of cherubism is known to be 100% for 
males and 50% to 70% for females, some clini-
cal studies have shown that mutation in this gene 
does not have 100% penetrance in males.2-4 Com-
mon clinical and radiographic signs of patients 
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with cherubism are painless bilateral expansion of 
the jaws, displaced and/or missing teeth or tooth 
germs, and multilocular well-defined radiolucent 
lesions. Histopathologic features of the afore-
mentioned lesions are similar to central giant cell 
granuloma (CGCG). Despite their stromal struc-
ture, cherubism lesions are spongier than CGCG 
lesions, and eosinophilic fibrolitic thickening has 
been evident.5 However, cherubism and CGCG le-
sions have similar findings and similar treatment 
options.  Conventional  treatment  of  CGCG  com-
prises local curettage and long-term follow-up. 
Despite the high success rate of surgical interven-
tions in the management of CGCG, conservative 
approaches like intralesional steroid injections,6 
subcutaneous administration of α-interferon fol-
lowing surgery,7 and systemic calcitonin therapy8 
have been advocated, and favorable results have 
been achieved. 
It has been reported that calcitonin therapy is 
a feasible treatment option in the management of 
CGCG, especially for larger aggressive or multiple 
lesions.9 However, few reports have been pub-
lished with regard to successfully treated CGCG-
like lesions of cherubism by calcitonin administra-
tion. In this case report, treatment of cherubism 
with 200 IU salmon calcitonin via nasal adminis-
tration is presented.
cAsE rEPort
A  14-year-old  boy  was  referred  to  our  clinic 
with a complaint of painless bilateral symmetric 
thickening of the lower jaw and dental disharmo-
ny. Extra-oral view of the patient exhibited bilater-
al swelling in the angular region of the mandible, 
which was relatively resolved with age, and bilat-
eral exophtalmus and bulb displacement (Figures 
1 and 2). Facial signs in the patient were present 
for more than 10 years. Panoramic radiograph of 
the patient revealed bilateral thickening of the 
mandible, irregular multiple multilocular radiolu-
cent areas and displaced teeth and tooth germs, 
as well as missing permanent teeth (Figure 3). The 
boundaries of the lesions were also determined by 
computerized  tomography  (CT)  scan  (Figure  4). 
Serum levels of parathyroid hormone and alkaline 
phosphatase were in the range of normal values. 
An incisional biopsy was performed under local 
anesthesia. The histopathologic characteristic of 
the lesion was consistent with CGCG, which dis-
plays oval-shaped fibrohistiocytic stromal cells 
and osteoclast-like multinuclear cells on hemor-
rhagic ground (Figure 5). The history of the patient 
and younger photographs of him revealed a sig-
nificant regression of swellings over the course of 
growth (Figure 1B). 
According to the history of the patient, clini-
cal and laboratory findings, and radiographic and 
histological examinations, a final diagnosis was 
cherubism. The family of the patient was informed 
about the prognosis of the disease because the 
other family members were free of cherubism 
Figure 1. Frontal views of the patient before calcitonin therapy (A) and at the time 
of early childhood (B).
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symptoms. Calcitonin therapy was initialized with 
salmon calcitonin every other day by use of a na-
sal spray (Calcitonina Hubber 200 IU, ICN Iberica, 
Spain). Periodical radiographic follow-up was 
performed in order to evaluate the efficacy of the 
treatment. After 30 months of treatment, signifi-
cant radiographic improvement was observed and 
calcitonin therapy was ceased (Figures 6 and 7). 
dIscussIon
The main findings of cherubism are bilateral 
symmetrical swelling in the angular region of the 
face and intra-osseous CGCG-like lesions in the 
jaws. Cherubism is a familial disorder, which has 
also been reported as a type of fibrous dysplasia 
of the jaws.10 A possible etiological pathway of 
cherubism and related CGCG lesions is related to 
dysregulation of mesenchymal bone subsequent 
to a disturbed cap stage of the second and third 
molar, which is induced by mutation in the SH3BP2 
gene.11 Although multiple family members in the 
same generation may be affected due to the au-
tosomal dominant characteristic of the disease, a 
lack of familial background could be observed12,13 
as in the present case.
Conventional treatment of cherubism includes 
jaw contouring, curettage of the lesions, and man-
agement of dental disharmony. Although there are 
many reports concerning regression of the cheru-
bic lesions in advanced ages,13 CGCG-like lesions 
in cherubism usually need to be treated, and fa-
vorable results have been obtained with calcitonin 
administration  in  the  management  of  CGCG.2,9,14 
Calcitonin therapy for CGCG was first described by 
Harris in 1993.8 The therapeutic effects of calci-
tonin may act on calcitonin receptors in the giant 
cells of the CGCG, and increased osteoclastic ac-
tivity in CGCG has been thought to be antagonized 
via calcitonin therapy.14,15 The use of calcitonin 
therapy for cherubism has been rarely document-
ed. In an in vitro study, the positive effects of cal-
citonin on bone resorption within cherubic lesions 
was proven.16 Lannon and Earley17 observed the 
therapeutic failure of 100 IU calcitonin therapy via 
daily subcutaneous injections for 6 months, and 
reported that no regression was observed. They 
stated that failure of calcitonin therapy is related 
to poor compliance by the patient, as well as the 
relatively short treatment period, and they con-
cluded that improved patient compliance might 
be obtained by using the intranasal method.  Hart 
et al18 performed one year of calcitonin therapy 
for cherubism via nasal administration, but they 
had to stop the treatment because of nausea. In 
a recent report, de Lange et al2 performed daily 
administration of 200 IU calcitonin via nasal spray 
for a 15-month period in a boy with cherubism and 
observed considerable regression of the lesion 
after cessation of therapy. Similar to the manner 
of therapy used by de Lange et al,2 in the present 
case, calcitonin was administered via the nasal 
passage for duration of more than two years. 
The severity of cherubic lesions varies case to 
case, and its severity has been classified by previ-
ous authors (grades 1, 2 and 3, according to sever-
ity of lesions).10,19,20 The course of treatment may 
vary according to the size of the lesion. The pres-
ent case might be considered as a grade 1 case 
of cherubism due to the fact that bilateral lesions 
occurred only in the posterior mandible, and the 
duration of the treatment was longer as well. No 
side effects were observed during the treatment 
period. 
The dose, type, and administration method 
of calcitonin has been documented in many re-
ports.2,8,9,14 Since calcitonin was first used for 
Figure 2. Bilateral bulb displacement.
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Figure 3. Panoramic radiograph before calcitonin therapy.
Figure 4. Computerized tomography view before calcitonin therapy. Figure 5. Histopathologic view of the lesion (HE ×400).
Figure 6. Panoramic radiograph after calcitonin therapy.European Journal of Dentistry
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CGCG, daily subcutaneous administration of hu-
man calcitonin has become the most common 
method of therapy. However, the use of salmon 
calcitonin has recently become more popular than 
using human calcitonin because of its increased 
potency and availability.21 The correct dose of cal-
citonin has been determined at 100 IU per day, 
which is based on the regimens previously used 
for Paget’s disease.22 On the other hand, the use 
of daily 200 IU salmon calcitonin via nasal spray 
for cherubism has been recently reported.2 In 
the present case, 200 IU calcitonin was adminis-
tered via nasal spray every-other-day to make an 
equivalent daily dose of 100 IU, because a 100 IU 
calcitonin nasal spray dosage was not available in 
the country. However, it is well known that daily 
subcutaneous administration of 100 IU calcitonin 
is considerably more effective than an every-oth-
er-day nasal dose of 200 IU. As a result, the two 
treatment regimens are not comparable due to 
the lower bio-availability of nasal spray. In gen-
eral, subcutaneous application was preferred in 
order to achieve efficient absorption. Neverthe-
less, the absorbed amount of calcitonin might be 
unpredictable because of the condition of the na-
sal mucosa. However, systemic calcitonin dosage 
via nasal spray is considered the easiest method 
of management, especially in children. 
To our knowledge, the present report is the 
second in which cherubic lesions were treated 
with systemic calcitonin administration via nasal 
spray for duration of more than one year. After 
approximately three years of treatment, calcito-
nin therapy was discontinued since radiographic 
regression of the lesions and growth of the pa-
tient had ended, and the patient was scheduled 
for follow-up. However, regression of the lesions 
through the natural course of the disease, due to 
the relatively older age of the patient, may have 
contributed to the successful outcome of the 
treatment. The dose and application method of 
calcitonin therapy would be dependent on the case 
and patient tolerability. A dosage of 200 IU calci-
tonin via nasal spray may be administered every 
other day in order to improve patient tolerability 
and continuity of the treatment, especially in mild 
cases of cherubism. Further studies will be nec-
essary to determine the ideal regimen of calcito-
nin therapy for cherubic individuals.
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